SCHEMBL1685405

SCHEMBL1685405

Cc1ccc(C2(c3ccccc3)NC(=O)NC2=O)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.79
CACNA1F O60840 1/20 0.79
ALDH1A1 P00352 1/20 0.79
MAPT P10636 1/20 0.79
HTR2A P28223 1/20 0.79
HRH1 P35367 1/20 0.79
SCN1A P35498 1/20 0.79
SCN4A P35499 1/20 0.79
BLM P54132 1/20 0.79
PMP22 Q01453 1/20 0.79
CACNA1D Q01668 1/20 0.79
KCNH2 Q12809 1/20 0.79
CACNA1S Q13698 1/20 0.79
CACNA1C Q13936 1/20 0.79
SCN5A Q14524 1/20 0.79
SCN2A Q99250 1/20 0.79
SCN3A Q9NY46 1/20 0.79
AKR1B1 P15121 1/20 0.70
ADAM17 P78536 1/20 0.56
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4560126 1.00 CYP2C9 (0.79) CYP2C9CACNA1FALDH1A1MAPTHTR2A
SCHEMBL10521481 0.93 CYP2C9 (0.64) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL5499612 0.89 CYP2C9 (1.00) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL3440 0.89 CYP2C9 (1.00) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL28905600 0.87 CYP2C9 (0.88) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL2140317 0.87 CYP2C9 (0.96) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL5160618 0.87 CYP2C9 (0.96) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL157671 0.87 CYP2C9 (0.96) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL2905857 0.87 CYP2C9 (0.96) CYP2C9CACNA1FALDH1A1MAPTHTR2A
Phenytoin SCHEMBL1461588 0.87 CYP2C9 (0.96) CYP2C9CACNA1FALDH1A1MAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114488123-B Radar data and camera data fusion method and system 超级视线科技有限公司 2025-02-11 CN claimed
CN-116630379-A Stacked workpiece shielding point cloud registration method and device based on grid feature description 浙江工业大学 2023-08-22 CN claimed
CN-115760945-A Method and system for acquiring stable target detection frame based on target detection 智慧互通科技股份有限公司 2023-03-07 CN claimed
CN-114488123-A Radar data and camera data fusion method and system 超级视线科技有限公司 2022-05-13 CN claimed
US-20260060969-A1 METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS INST NAT SANTE RECH MED (FR) 2026-03-05 US disclosed
US-12565505-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2026-03-03 US disclosed
US-20260000658-A1 METHODS FOR THE TREATMENT OF PROLIFERATIVE GLOMERULONEPHRITIS INST NAT SANTE RECH MED (FR) 2026-01-01 US disclosed
US-20250346693-A1 HIGH-PERFORMANCE ZIEGLER CATALYST FOR LOOP-SLURRY PROCESS EQUISTAR CHEMICALS, LP (US) 2025-11-13 US disclosed
US-20250244751-A1 SMART LOADING OPTIMIZER ENGINE (SLOPE) USING ARTIFICIAL INTELLIGENCE SAUDI ARABIAN OIL COMPANY (SA) 2025-07-31 US disclosed
US-20250223297-A1 NOVEL RAPAMYCIN DERIVATIVES NOVARTIS AG (CH) 2025-07-10 US disclosed
EP-4565217-A1 METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS Institut National de la Santé et de la Recherche Médicale (FR) 2025-06-11 EP disclosed
CN-119954829-A MTORC1 modulators and uses thereof 艾奥维安制药公司 2025-05-09 CN disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed
EP-1860434-A1 Method for analysing substance mixtures Shimadzu Europa GmbH (DE) 2007-11-28 EP disclosed
EP-0893453-B1 Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis BECKMAN COULTER INC (US) 2004-04-07 EP disclosed
US-6316613-B1 USED TO SEPARATE OPTICAL ISOMERS BECKMAN COULTER, INC. 2001-11-13 US disclosed
EP-0893453-A2 Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis Beckman Coulter, Inc. (US) 1999-01-27 EP disclosed
US-5098576-A Nonporous silicon carbide as adsorbants for liquid chromatography MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1992-03-24 US disclosed
EP-0368138-A1 Adsorbent for chromatography MERCK PATENT GmbH (DE) 1990-05-16 EP disclosed
US-4006232-A Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins MILES LABORATORIES, INC. (US) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565505-B2 mTORC modulators and uses thereof RICTOR, MTOR, RPTOR CYP2C9 3342/4885CACNA1F 1963/4885ALDH1A1 4613/4885
US-20260000658-A1 METHODS FOR THE TREATMENT OF PROLIFERATIVE GLOMERULONEPHRITIS PIK3R4, PIK3CA, PIK3R5 CYP2C9 3713/4885CACNA1F 4252/4885ALDH1A1 4742/4885
US-20250223297-A1 NOVEL RAPAMYCIN DERIVATIVES MTOR, RICTOR, RPTOR CYP2C9 3285/4885CACNA1F 3735/4885ALDH1A1 4143/4885
US-20260060969-A1 METHODS FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS PIK3R4, PIK3R5, PIK3R1 CYP2C9 3039/4885CACNA1F 2723/4885ALDH1A1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.